ACVRL1 and atherosclerosis: Here, Lee et al. show that genetic ablation of arterial endothelial ALK1 in mice limits atherosclerosis without affecting cholesterol or triglyceride levels and that a monoclonal antibody binding ALK1 efficiently blocks LDL transcytosis, but not BMP9 signaling, leading to a reduction in plaque burden.